Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SAMN03290947

—

66223c4e-dc39-51e9-9193-2fa790fa54eb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.600
  • INTERFERON_GAMMA_RESPONSE+0.600
  • ALLOGRAFT_REJECTION+0.500
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • MITOTIC_SPINDLE+0.500
  • PI3K_AKT_MTOR_SIGNALING+0.500
  • COMPLEMENT+0.400
  • G2M_CHECKPOINT+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.400

Top 10 suppressed

  • DNA_REPAIR-0.300
  • MYC_TARGETS_V2-0.300
  • MYC_TARGETS_V1-0.200
  • MYOGENESIS-0.200
  • COAGULATION-0.100
  • OXIDATIVE_PHOSPHORYLATION-0.100
  • PANCREAS_BETA_CELLS-0.100
  • SPERMATOGENESIS-0.100
  • BILE_ACID_METABOLISM+0.000
  • CHOLESTEROL_HOMEOSTASIS+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1957a7228-3558-48fd-81d9-13f951e0b597
melanoma-umap@29
——0.904
2TCGA-44-6779-01A-11R-1858-07
lung-landscapes@6
—cohortA10.859
3BS_0SCXXM6N
brain-umap@2
low-grade glioma—0.839
4SRR35579823
breast-umap@18
—D0.835
5MNG736
mng-umap@100
——0.824
6TCGA-CN-4734-01A-01R-1436-07
head-neck@1
——0.822
7TCGA-AR-A0TX-01A-11R-A084-07
breast-umap@18
—C0.820
8MDT-AP-3337
medullo-epn-umap@date-based
MedMedulloblastoma0.818
9TCGA-DK-A2I4-01A-11R-A21D-07
bladder-landscape@3
——0.817
10SRR934743
brain-umap@2
——0.816

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.600Idelalisib— uncovered
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
MITOTIC_SPINDLE0.500Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.500Inavolisib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.400Inavolisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
PROTEIN_SECRETION0.300Remibrutinib— uncovered
UV_RESPONSE_DN0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered